This article summarize principal news about treatments in the different specialities in neurology. We don't pretend to be exhaustive and to make a detailed analyse of all treatments, and preferred to present pertinent therapeutic advances, with an evidence-based point of view. We also mentioned some negative studies, to balance our purpose.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
What's in a Name: Your PLEX or PEX Is Our TPE.
J Clin Apher
December 2024
Department of Pathology and Genomic Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
In the American Society for Apheresis (ASFA) guidelines, the abbreviation for therapeutic plasma exchange is standardized as TPE. However, the term PLEX (derived from PLasma EXchange), among others, is not infrequently encountered in clinical practice and in publications. Search queries were performed in PubMed using therapeutic plasma exchange, plasma exchange, "therapeutic plasma exchange," "plasma exchange," TPE plasma, PLEX plasma, PEX plasma, TPE, PLEX, and PEX.
View Article and Find Full Text PDFAlzheimer Disease-What's in a Name?
JAMA Neurol
December 2024
Departments of Pathology and Neurological Sciences, Rush University Medical Center, Chicago, Illinois.
What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease.
eNeuro
September 2024
Department of Neurology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, and the GH Sergievsky Center, Columbia University Irving Medical Center, New York, New York 10032
Article Synopsis
- The FDA approved aducanumab in 2021, marking a significant breakthrough in Alzheimer's disease treatment, with two more drugs, lecanemab and donanemab, receiving similar approvals in early 2023 and mid-2024.
- These therapies, which target β-amyloid aggregates, have shown promising results in slowing cognitive decline in clinical trials.
- Ongoing discussions focus on the application of trial results to real-world scenarios and the overall long-term benefits of these treatments, along with the implications of FDA approval conditions on their usage in clinical practice.
[Epileptic syndromes in pediatrics. What's new?].
Medicina (B Aires)
September 2024
Neurology Department, Nationwide Children's Hospital, The Ohio State University, USA.
The classification of epilepsy syndromes in pediatrics has undergone significant changes. In 2017, the International League Against Epilepsy Task Force on Nosology and Definitions proposed a new classification and definition and established mandatory, exclusionary, and alert criteria for the diagnosis of the different syndromes. The goal of this article is not to provide an extensive review of each syndrome, but to focus on syndromes that suffered important changes in terminology and/or when consensus or new methods to improve diagnosis and treatment have been designed.
View Article and Find Full Text PDFMorphometry of medial temporal lobe subregions using high-resolution T2-weighted MRI in ADNI3: Why, how, and what's next?
Alzheimers Dement
November 2024
Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
This paper for the 20th anniversary of the Alzheimer's Disease Neuroimaging Initiative (ADNI) provides an overview of magnetic resonance imaging (MRI) of medial temporal lobe (MTL) subregions in ADNI using a dedicated high-resolution T2-weighted sequence. A review of the work that supported the inclusion of this imaging modality into ADNI Phase 3 is followed by a brief description of the ADNI MTL imaging and analysis protocols and a summary of studies that have used these data. This review is supplemented by a new study that uses novel surface-based tools to characterize MTL neurodegeneration across biomarker-defined AD stages.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!